The robotic surgery market loves a good tower. Those multi-armed machines dominating operating rooms—Intuitive Surgical's da Vinci chief among them—command both attention and floor space. But what if you could skip the tower altogether?
That's the pitch from Channel Robotics, a Del Mar, California startup spun out of UC San Diego. The company has spent the past year quietly raising a seed round led by Old Line Capital Partners, according to a LinkedIn announcement the company posted this spring. Old Line, which describes itself as Channel's first institutional backer, made a significant investment that closed in December 2025—though neither party has been eager to discuss how much money actually changed hands.
It's a modest start for ambitious technology. Channel's system—a handheld controller called Channel ONE paired with a disposable instrument, the EC180—is designed to snap onto standard endoscopes without requiring the infrastructure that typically accompanies surgical robotics. The company promises sub-millimeter precision and what it calls "robotic-grade dexterity," all in a package that could fit in a gastroenterologist's hands.
Whether that's enough to crack a market dominated by entrenched players remains an open question.
From Research Lab to Operating Room
Channel Robotics emerged in 2023 from the kind of academic collaboration that universities dream about. Dr. Philip Weissbrod, a board-certified ear, nose, and throat surgeon on the UCSD medical faculty, joined forces with Dr. Michael Yip, an electrical and computer engineering professor who runs the university's Advanced Robotics and Controls Lab. Last November, the pair picked up UCSD's Institute for the Global Entrepreneur Faculty Innovator of the Year honors—a recognition that doesn't hurt when pitching investors.
The company's initial target is gastrointestinal procedures: colonoscopies, endoscopic submucosal dissections, the kinds of delicate work where a slip of the hand can mean the difference between a routine outpatient case and an emergency surgery. Channel's bet, as outlined in coverage by Life Science Intelligence last fall, is that better reach and stability in winding anatomy could keep patients out of the OR entirely.
Still, the path from prototype to FDA clearance is rarely smooth. As of late 2025, Channel had been targeting a 510(k) submission for the second quarter of 2026, with hopes of early clinical use by late 2026. As of early summer, no public filing has surfaced—though that may say more about FDA timelines than the company's progress. By November, Channel had wrapped Phase 1 industrial design and completed bench and cadaveric testing, with plans to move into design-for-manufacturing within six months.
Perhaps the silence simply means they're keeping their heads down.
Money Matters
The seed round represents a step up from Channel's earlier fundraising efforts. In November 2024, the company filed paperwork with the SEC for a $2 million debt offering, having pulled in roughly $305,000 from ten investors at the time. Old Line's backing—formalized after what the investment firm described as months of collaboration beginning last spring—suggests the startup has progressed enough to justify institutional capital, even if the exact figures remain under wraps.
Old Line Capital Partners announced its involvement in a press release last December, emphasizing its role as Channel's inaugural institutional investor. What the firm saw in Channel, beyond the academic pedigree, likely includes the same calculus driving interest across the surgical robotics sector: explosive growth projections and a market that hasn't yet picked all its winners.
A Crowded, Lucrative Arena
Channel is hardly alone in chasing handheld or minimalist robotic solutions for endoscopy. Grand View Research valued the broader surgical robotics market at $6.6 billion in 2025, with forecasts suggesting it could hit $18.5 billion by 2033. Intuitive Surgical alone posted more than $10 billion in revenue last year—a figure that tends to make upstarts salivate and investors pay attention.
But competition in the endoscopic robotics niche is thickening fast. EndoQuest closed a Series D-2 round last July. Singapore-based EndoMaster is advancing its own platform. Olympus, the endoscopy incumbent, has thrown its weight behind Swan EndoSurgical in a partnership that could unlock up to $458 million if the stars align and milestones get hit.
Against that backdrop, Channel's handheld pitch has appeal—assuming doctors actually want it, hospitals will pay for it, and the technology works as advertised when things get messy. None of that is guaranteed.
The Long Game
Channel Robotics picked up another credential this year: a spot in Connect San Diego's Cool Companies cohort for 2026, joining the region's startup showcase circuit. The company also presented at LSI USA '26 in March, part of the well-trodden path for medical device startups hunting visibility and funding.
What happens next depends on regulatory approvals, clinical data, and whether Channel can deliver on the promise that simpler can be better. In a market where "robotic" often means "massive and expensive," a handheld alternative sounds almost heretical.
Then again, heresy occasionally works.
